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Introduction
The Fcg receptor (FcgR) family is composed of several receptors, the ligation of which with immunoglobulin (Ig)G leads to opposite signals. Activating receptors are represented by FcgRI (CD64), FcgRIIa/c (CD32a/c) and FcgRIII (CD16), whereas FcgRIIb (CD32b) gives an inhibitory signal [1] . As most of the monocytes/macrophages express both activating and inhibitory FcgR, the activating threshold to the ligation of IgG is tuned by the ratio of activator/inhibitory receptors. Imbalance between activating and inhibitory FcgR has been involved in various other autoimmune diseases than immune thrombocytopenia (ITP), such as systemic lupus erythematosus [2] and rheumatoid arthritis [3, 4] . Evidence is also provided by animal models such as CD32B -/-mice that develop lupus-like disease [1] . Conversely, the up-regulation of CD32b in lupus-prone mice strains, such as NZB and BXSB, restores tolerance and reduces autoimmune manifestations [5] .
ITP is an autoimmune disease responsible for a peripheral immune destruction of platelets [6] . In most cases the disease is caused by autoreactive B cells producing autoantibodies targeting glycoproteins (GP) expressed on platelet membrane, such as GPIIb/IIIa, GPIb/IX and/or GPIa/IIa [7, 8] . Subsequently, autoantibody-opsonized platelets are phagocytosed by splenic macrophages in a FcgR-dependent mechanism [9] . Consistent with the role of FcgR in ITP pathogenesis, IVIg, the mechanism of action of which is due partly to interaction with FcgR [10] , has been used for more than 30 years to increase platelet count during ITP [11, 12] . It has also been shown in a pilot study that syk-inhibitors, by interfering with the FcgR signalling pathway, can improve ITP [13] . Recently, it has been shown on monocyte-derived macrophages that the effect of IVIg was mediated by the blockade of activating receptors and was independent of IgG sialylation and FcgRIIb expression [14] , conversely to what has been observed in murine models [15, 16] .
As well as the level of expression and the type of FcgR, polymorphisms of FcgR can also participate in ITP pathogenesis, the FCGR3A-158V/F polymorphism, which leads to a stronger affinity to IgG, is increased in childhood ITP [17] [18] [19] [20] ; the prevalence of the open reading frame (ORF) of FCGR2C, encoding an activator receptor, is increased during ITP [21] and the FCGR2B-232I/T genotype is observed preferentially in children ITP with a chronic course [22] .
Until now, data concerning human splenic macrophage phenotype and function have been scarce, particularly during ITP, in which the spleen is the major place of platelet destruction [23] and the primary site of maintenance of the autoimmune response [9] . We thus took advantage of splenectomy as part of the treatment of ITP to study for the first time the expression and polymorphism of FcgR on human splenic macrophages from ITP patients treated or not with IVIg prior to splenectomy compared to posttraumatic control spleens.
Materials and methods

Patients
ITP patients, admitted to the University Hospital of Dijon, France, were enrolled into the study after giving written informed consent in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board and the Research Ethic Review Committee of the University Hospital of Dijon. The main inclusion criterion was primary immune thrombocytopenia, i.e. a platelet count below 100 G/l with exclusion of familial, viral, drug-induced or systemic autoimmune disease-related thrombocytopenia. Treatments were initiated when platelet count was below 30 G/l with steroids for 3-4 weeks and, if necessary, with intravenous Ig (IVIg) [26] as first-line therapy. The spleens of 24 ITP patients (Table 1) were available for flow cytometry (FCM), phagocytosis assay and multiplex ligation-dependent probe amplification (MLPA). Post-traumatic spleens (n 5 6) were used as controls.
Spleen preparation
Splenocytes were obtained as described previously [27] and stored in liquid nitrogen until needed. Cells were thawed rapidly and washed before use.
Flow cytometry
The following antibodies were used: anti-CD14 allophycocyanin (APC)-Hilite7, anti-CD16 Brilliant Violet 500, CD206 APC (BD Biosciences, San Jose, CA, USA), antiCD32a fluorescein isothiocyanate (FITC) (clone IV.3; Stemcell Technologies, Vancouver, Canada), anti-CD32b Alexa Fluor 480 (clone 2B6; MacroGenics, Rockville, MD, USA), anti-CD64 phycoerytrin (PE) (Dako, Carpenteria, CA, USA), anti-human leucocyte antigen D-related (HLA-DR) Pacific Blue and anti-CD163 peridinin chlorophyll protein complex (PerCP)-cyanin5.5 (Biolegend, San Diego, CA, USA). Importantly, anti-CD32a clone IV.3 antibody, has been shown to bind specifically to CD32a but not to CD32b [28, 29] . Similarly, anti-CD32b clone 2B6 antibody does not bind to CD32a, but to CD32b, as shown by enzyme-linked immunosorbent assay and fluorescence activated cell sorter (FACS) staining of specific cell lines and CD32B-transfected cells [29] . However, it has been shown recently to bind to CD32c, the expression of which 
Phagocytosis assay
The isolation of splenic macrophages was performed with CD14 microbeads (Miltenyi Biotec, San Diego, CA, USA) on AutoMACS V R following the manufacturer's instructions (Miltenyi Biotec). Macrophages (5Á10 5 /ml) were suspended in RPMI supplemented with fetal bovine serum (FBS) (10%) and incubated with streptavidin FITC-fluorospheres (2 mM diameter fluorescent microspheres (Fluoresbrite V R ); Polysciences, Warrington, PA, USA) at a ratio of 1 : 10 for 1 h at either 48C or 378C in flat-bottomed 96-well plates. Fluorospheres were used uncoated or coated with human biotinylated IgG. Cells were collected by washing with cold PBS. In some experiments, FcgR on macrophages were blocked using FcgR blocking agent (Miltenyi Biotec) for 10 min before adding fluorospheres. Phagocytosis was checked on a fluorescence microscope (EVOS V R ). The phagocytosis index was defined as the ratio of stained macrophages at 378C compared to that at 48C. Data were acquired on a BD Biosciences LSRII TM cytometer and analysed with FlowJo TM software.
Multiplex ligation-dependent probe amplification
MLPA was used to analyse single nucleotide polymorphisms (SNP) in FCGR2A (131H/R), FCGR2B (232I/T), promoter of FCGR2B and FCGR2C (2386G/C), FCGR3A (158V/F) and FCGR3B (HNA1a/1b/1c), as described previously [21] . As the size of the spleen control group was too small to allow reliable comparison, 200 controls from a previously described cohort [21] were included in the analysis.
Statistics
Student's or paired t-tests were used to compare quantitative variables as appropriate. Fisher's exact test or Pearson's v 2 test were used to compare qualitative data as appropriate. Analysis of variance with a Bonferroni correction was performed when more than two variables were compared. Results were considered statistically significant when P < 0Á05. Results are given by mean 6 standard error of the mean. Analyses were performed on GraphPad Prism V R , San Diego, CA, USA.
Results
Patient's characteristics
The mean age of patients was 46.7 6 5 years at splenectomy (Table 1) . Seventy per cent were female (17 of 24). Patients had an active disease with a lowest platelet count of 19Á4 6 2 G/l within the 3 months prior to splenectomy. The mean disease duration at splenectomy was 29 6 5 months. All patients were first treated with steroids, followed by dapsone (54Á1%), rituximab (37Á5%) and thrombopoietin receptor agonist (TPO-RA, 8Á3%). IVIg were used as rescue therapy in 79Á1%. The response rate of splenectomy was 79% (19 of 24). Refractory patients were older than responders (67Á8 6 11 versus 41Á2 6 5, P 5 0Á02), and tended to have a lower platelet count than responders (13Á8 6 2Á5 versus 21Á4 6 1Á8, P 5 0Á04). Disease duration at splenectomy was not different between responders and refractory patients. A platelet count above 50 G/l was required to perform splenectomy: 14 patients received IVIg within the 2 weeks prior to splenectomy, whereas eight patients received either steroids (n 5 6), TPO-RA (n 5 1) or no treatment (n 5 1; Table 1 ). The mean platelet count before splenectomy was 195 6 26 G/l. The use of either steroids or IVIg was determined by the physician managing the patient. The patient treated with TPO-RA was refractory to both steroids and IVIg. The patient who did not receive any treatment had a spontaneous platelet count above 50 G/l, but splenectomy was indicated because of a suspect splenic nodule that was finally consistent with a primary angiomyolipoma.
FCGR3A (158V/F) polymorphism is over-represented in ITP
Because some polymorphisms of FcgR can modulate their activity or expression, the most common SNPs of the different FCGR were analysed. The allele frequency of FCGR2A-131H/R, FCGR2B-232I/T and FCGR3B-HNA1a/ 1b/1c were not significantly different between patients and controls ( Table 2) . Concerning FCGR3A, an overrepresentation of FCGR3A-158V during ITP (50% versus 30.6%, P 5 0Á016) was observed ( Table 2) .
The ORF of the FCGR2C is due to a SNP in exon 3 that leads to the expression of an activating receptor, CD32c, excepted when associated with a second mutation in exon 7 (non-classical ORF), resulting in a STOP codon and the absence of expression of CD32c [30] . There was no significant difference in allele frequency between patients and controls.
Splenic macrophages of ITP patients express higher CD86 and HLA-DR than controls
The expression of the different FcgR (CD16/FcgRIII, CD32a/FcgRIIa, CD32b/FcgRIIb and CD64/FcgRI) on human splenic macrophages was first assessed by flow cytometry (Fig. 1a) . Overall, CD16, CD32a and CD64 were expressed by more than 90% of splenic macrophages, when CD32b was expressed by an average of only 30%. Splenic macrophages also expressed CD86 and HLA-DR (95Á2 and 98Á9%, respectively). The scavenger receptor CD163 was expressed by an average of 61%, whereas the mannose receptor (CD206) was expressed by only 13Á4% of splenic macrophages.
The expression rate of the different markers was compared using median fluorescence intensity (MFI). Because of the extracellular domain homology between CD32b and , with exclusion of FCGR2C-ORF patients for CD32b and CD32a/CD32b expression. Results are summarized in dot-plots. The horizontal bar represents the mean with the standard error of the mean. P-value derived by Student's t-test; n.s. 5 non-significant; *P < 0Á05; **P < 0Á01. CD32c, they are both recognized by clone 2B6 [30] . Thus, the presence of FCGR2C-ORF, leading to CD32c expression, was associated with a high MFI of CD32b/c (> 1000) in one control and six patients (Fig. 1b) . Considering that CD32c is an activating receptor, analyses of the expression of CD32b and the balance between activating and inhibitory FcgR represented by the CD32a/CD32b ratio were performed with exclusion of FCGR2C-ORF patients. No difference in the expression of FcgRs on splenic macrophages was observed between ITP patients and controls (Fig. 1c) . The balance between activating and inhibitory FcgR represented by the CD32a : CD32b ratio was similar between the two groups. On the contrary, HLA-DR expression was higher during ITP compared to controls (9634 6 694 versus 6718 6 628, P 5 0Á04). Similarly, the activation molecule CD86 was expressed more highly during ITP compared to controls (4553 6 206 versus 3232 6 440, P 5 0Á009). The expression of CD163 and CD206 was not different between the two groups.
Splenic macrophage phenotype was also compared between ITP patients, depending on the response to splenectomy. Nineteen (79%) patients who were in remission after splenectomy were compared to five refractory patients. No difference in the expression of the different markers on splenic macrophages was observed (Supporting information, Fig. S1 ).
The use of IVIg prior to splenectomy does not affect the expression of FcgR and activation markers on human splenic macrophages To determine whether IVIg could affect the expression of the different FcgR and activation markers on splenic macrophages in vivo, their phenotype was compared between ITP patients, depending on the use or not of IVIg prior to splenectomy. No difference was observed between the two groups regarding the expression of the different FcgR or the CD32a/CD32b ratio. The expression of HLA-DR, CD86, CD163 and CD206 was also similar between groups (Fig. 1c) .
Phagocytosis by splenic macrophages is decreased after IVIg treatment during ITP
In addition to macrophage phenotype, their functionality was determined by comparing their phagocytic capacity (Fig. 2a, b) and compared between three controls and six ITP patients treated with IVIg prior to splenectomy. A significant decrease in the phagocytosis index between controls and ITP patients was observed when using unopsonized fluorescent beads (2Á6 6 0Á5 versus 1Á4 6 0Á2, respectively; P 5 0Á04; Fig. 2c ). The phagocytosis index also tended to be lower when human IgG-coated fluorospheres were used (3Á2 6 1 versus 2Á3 6 0Á3; P 5 0Á3; Fig. 2c). Overall, the phagocytosis index was higher when IgGcoated fluorospheres were used, compared to uncoated beads (1Á5 6 0Á4 versus 2Á7 6 0Á6, P 5 0Á02; Fig. 2c ). This increase was abrogated by FcgR blockade (2Á7 6 0Á6 versus 1Á5 6 0Á3, P 5 0Á02; FigÁ 2c), thus confirming the role of FcgR during the phagocytosis process.
Discussion
An increase in CD64 expression and in the CD32a/CD32b ratio has been described on circulating monocytes during ITP [31] . As thrombocytopenia is mediated mainly by splenic macrophages during ITP, our aim was to investigate their phagocyte function and FcgR expression. To date, whether IVIg modulate CD32b expression on macrophages in humans in vivo is not known, and has been extrapolated from mouse models. Moreover, the results concerning the modulation of CD32b by IVIg are debated, as the first reports showed that the effects of IVIg rely on CD32b expression [32] , which was increased after IVIg infusion [16] , whereas others demonstrated that IVIg efficacy did not depend on CD32b [33] .
During ITP, CD32b expression by splenic human macrophages has been assessed in only one study [34] , which showed a decrease in CD32b expression determined by immunochemistry. We do not confirm this result by measuring CD32b expression using flow cytometry, which is a more sensitive technique. Moreover, our results are in line with more recent publications that reported the absence of variation of CD32b expression on circulating monocytes in children ITP following IVIg [35] , and that the inhibition of FcgR mediated phagocytosis by monocyte-derived macrophages was independent of CD32b in vitro [14] . However, as the expression of FcgR on human splenic macrophages could not be assessed before and after IVIg treatment in vivo, patients were compared according to the treatment they received prior to splenectomy. The expression of FcgR was not different between the two groups, suggesting that IVIg do not modulate FcgR expression in vivo in humans. However, it cannot be excluded that this absence of difference in FcgR expression could be due to similar effects of the treatments used in these patients, as steroids and TPO-RA have been shown to shift the balance of FcgR towards inhibitory CD32b on circulating monocytes during ITP [31, 36] . We also show here for the first time, to our knowledge, that splenic macrophages from ITP patients have a decreased phagocytic function in vivo, due probably to IVIg used prior to surgery. Taken together, our results show that, in vivo, IVIg do not seem to modulate FcgR expression, notably CD32b, but induce a decrease in phagocytic capability of splenic macrophages.
Because not only the expression level but also the affinity between antibody and FcgR could play a role in antibodymediated diseases, we investigated the presence of different SNPs of FcgR. In this cohort, we observed an overrepresentation of FCGR3A2158V, as reported previously in children with ITP [17, 20, 21] , a polymorphism known to increase the affinity of the receptor CD16 to IgG [37] .
Interestingly, human splenic macrophages in ITP showed an increase in HLA-DR and CD86 expression compared to controls, consistent with a higher activation state. Such an increase in the co-stimulatory molecule CD86 has already been observed in monocyte-derived dendritic cells, and was associated with an increase in CD4
1 T cell proliferation [38] . The higher activation status on splenic macrophages of ITP patients probably participates in CD4 1 T cell activation and to the maintenance of the autoimmune response, as macrophages are the main T cell activators in the spleen compared to dendritic cells [9] . However, this activated status was not correlated with the response to splenectomy.
In conclusion, we showed here that the expression of the different FcgR on splenic macrophages is not different between ITP patients and controls, whereas these cells display a higher expression of activation markers such as CD86 and HLA-DR in accordance with their major role of antigen-presenting cells in ITP. Furthermore, we also demonstrated that IVIg used prior to splenectomy during ITP leads to a decrease in phagocytic function of splenic macrophages.
